Trending: Bristol Myers Squibb to Buy RayzeBio
December 26 2023 - 9:28AM
Dow Jones News
0958 ET -- Bristol Myers Squibb is one of the most mentioned
companies in the U.S. across all news items in the last 12 hours,
according to Factiva data. The drugmaker has agreed to buy
radiopharmaceutical therapeutics company RayzeBio for $4.1 billion.
Dow Jones & Co. owns Factiva. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
December 26, 2023 10:13 ET (15:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
RayzeBio (NASDAQ:RYZB)
Historical Stock Chart
From May 2024 to Jun 2024
RayzeBio (NASDAQ:RYZB)
Historical Stock Chart
From Jun 2023 to Jun 2024